PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 23, 2026American Journal of Dermatopathology1 citations

Cutaneous T-Cell Lymphoma–Like Eruption from Trimethoprim–Sulfamethoxazole

View Full Paper
CBCarole BitarTulane UniversityAWAlexys WrightTulane UniversityAGAlyssa GuilloryTulane University

Key Points

  • The aim is to illustrate the occurrence of cutaneous pseudolymphoma due to trimethoprim-sulfamethoxazole in a patient with systemic lupus.
  • Case report involving clinical, histopathologic, and immunophenotypic evaluations.
  • Correlation of findings with patient history and treatment.
  • Follow-up assessment of skin condition.
  • Identification of a cutaneous T-cell lymphoma-like eruption attributed to trimethoprim-sulfamethoxazole.
  • Immunophenotypic and histopathologic findings confirm diagnosis.
  • Successful correlation with the patient's systemic lupus condition.

Abstract

Abstract: Cutaneous pseudolymphoma is a benign reactive process that comprises a heterogeneous group of entities that resembles lymphoma clinically and/or histologically. This condition can be idiopathic or caused by drugs, infections, or foreign agents. Cutaneous pseudolymphoma could belong to the B-cell type, the T-cell type, or be mixed. The multiple presentations raise a significant diagnostic challenge and require clinicopathologic correlation and follow-up. This case report presents the clinical, histopathologic, immunophenotypic, and genetic findings of a cutaneous T-cell lymphoma-like eruption from trimethoprim–sulfamethoxazole in a 55-year-old female systemic lupus patient.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Bitar et al. (2026) studied this question.

synapsesocial.com/papers/69e9ba6b85696592c86ec98dhttps://doi.org/10.1097/dad.0000000000003307
Ask AI
Helpful
Bookmark
Share
View Full Paper